Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 23, 2016

Primary Completion Date

August 21, 2019

Study Completion Date

December 31, 2025

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle

DRUG

Paclitaxel

Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle

DRUG

Capecitabine

Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.

Trial Locations (2)

90048

Cedars-Sinai Medical Center, Los Angeles

97213

Providence Cancer Center, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Providence Health & Services

OTHER

NCT02734290 - Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | Biotech Hunter | Biotech Hunter